Cargando…
Risk of Mortality among Patients with Gastrointestinal Bleeding with Early and Late Treatment with Tranexamic Acid: A Population-Based Cohort Study
Tranexamic acid (TXA) is an antifibrinolytic pharmacological agent, but its use in gastrointestinal bleeding remains contentious. Moreover, studies on the timing of TXA administration are limited. We examined whether early TXA administration reduced the risk of mortality in patients with gastrointes...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951209/ https://www.ncbi.nlm.nih.gov/pubmed/35330064 http://dx.doi.org/10.3390/jcm11061741 |
_version_ | 1784675328990380032 |
---|---|
author | Ting, Ke-Hsin Shiu, Bei-Hao Yang, Shun-Fa Liao, Pei-Lun Huang, Jing-Yang Chen, Yin-Yang Yeh, Chao-Bin |
author_facet | Ting, Ke-Hsin Shiu, Bei-Hao Yang, Shun-Fa Liao, Pei-Lun Huang, Jing-Yang Chen, Yin-Yang Yeh, Chao-Bin |
author_sort | Ting, Ke-Hsin |
collection | PubMed |
description | Tranexamic acid (TXA) is an antifibrinolytic pharmacological agent, but its use in gastrointestinal bleeding remains contentious. Moreover, studies on the timing of TXA administration are limited. We examined whether early TXA administration reduced the risk of mortality in patients with gastrointestinal bleeding in a Taiwanese population. We used the National Health Insurance Research Database to identify patients diagnosed with gastrointestinal bleeding with early and late TXA treatment. We defined early treatment as initial TXA treatment in an emergency department and late treatment as initial TXA treatment after hospitalization. Mortality within 52 weeks was the primary outcome. A multivariable analysis using a multiple Cox regression model was applied for data analysis. Propensity score matching (PSM) was performed to reduce the potential for bias caused by measured confounding variables. Of the 52,949 selected patients with gastrointestinal bleeding, 5127 were assigned to either an early or late TXA treatment group after PSM. The incidence of mortality was significantly decreased during the first and fourth weeks (adjusted HR (aHR): 0.65, 95% CI: 0.56–0.75). A Kaplan–Meier curve revealed a significant decrease in cumulative incidence of mortality in the early TXA treatment group (log-rank test: p < 0.0001). Multiple Cox regression analysis revealed significantly lower mortality in the early TXA treatment group compared with the late treatment group (aHR: 0.64, 95% CI: 0.57–0.73). Thromboembolic events were not significantly associated with early or late TXA treatment (aHR: 1.03, 95% CI: 0.94–1.12). A Kaplan–Meier curve also revealed no significant difference in either venous or arterial events (log-rank test: p = 0.3654 and 0.0975, respectively). In conclusion, early TXA treatment was associated with a reduced risk of mortality in patients with gastrointestinal bleeding compared with late treatment, without an increase in thromboembolic events. The risk of rebleeding and need for urgent endoscopic intervention require further randomized clinical trials. |
format | Online Article Text |
id | pubmed-8951209 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89512092022-03-26 Risk of Mortality among Patients with Gastrointestinal Bleeding with Early and Late Treatment with Tranexamic Acid: A Population-Based Cohort Study Ting, Ke-Hsin Shiu, Bei-Hao Yang, Shun-Fa Liao, Pei-Lun Huang, Jing-Yang Chen, Yin-Yang Yeh, Chao-Bin J Clin Med Article Tranexamic acid (TXA) is an antifibrinolytic pharmacological agent, but its use in gastrointestinal bleeding remains contentious. Moreover, studies on the timing of TXA administration are limited. We examined whether early TXA administration reduced the risk of mortality in patients with gastrointestinal bleeding in a Taiwanese population. We used the National Health Insurance Research Database to identify patients diagnosed with gastrointestinal bleeding with early and late TXA treatment. We defined early treatment as initial TXA treatment in an emergency department and late treatment as initial TXA treatment after hospitalization. Mortality within 52 weeks was the primary outcome. A multivariable analysis using a multiple Cox regression model was applied for data analysis. Propensity score matching (PSM) was performed to reduce the potential for bias caused by measured confounding variables. Of the 52,949 selected patients with gastrointestinal bleeding, 5127 were assigned to either an early or late TXA treatment group after PSM. The incidence of mortality was significantly decreased during the first and fourth weeks (adjusted HR (aHR): 0.65, 95% CI: 0.56–0.75). A Kaplan–Meier curve revealed a significant decrease in cumulative incidence of mortality in the early TXA treatment group (log-rank test: p < 0.0001). Multiple Cox regression analysis revealed significantly lower mortality in the early TXA treatment group compared with the late treatment group (aHR: 0.64, 95% CI: 0.57–0.73). Thromboembolic events were not significantly associated with early or late TXA treatment (aHR: 1.03, 95% CI: 0.94–1.12). A Kaplan–Meier curve also revealed no significant difference in either venous or arterial events (log-rank test: p = 0.3654 and 0.0975, respectively). In conclusion, early TXA treatment was associated with a reduced risk of mortality in patients with gastrointestinal bleeding compared with late treatment, without an increase in thromboembolic events. The risk of rebleeding and need for urgent endoscopic intervention require further randomized clinical trials. MDPI 2022-03-21 /pmc/articles/PMC8951209/ /pubmed/35330064 http://dx.doi.org/10.3390/jcm11061741 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ting, Ke-Hsin Shiu, Bei-Hao Yang, Shun-Fa Liao, Pei-Lun Huang, Jing-Yang Chen, Yin-Yang Yeh, Chao-Bin Risk of Mortality among Patients with Gastrointestinal Bleeding with Early and Late Treatment with Tranexamic Acid: A Population-Based Cohort Study |
title | Risk of Mortality among Patients with Gastrointestinal Bleeding with Early and Late Treatment with Tranexamic Acid: A Population-Based Cohort Study |
title_full | Risk of Mortality among Patients with Gastrointestinal Bleeding with Early and Late Treatment with Tranexamic Acid: A Population-Based Cohort Study |
title_fullStr | Risk of Mortality among Patients with Gastrointestinal Bleeding with Early and Late Treatment with Tranexamic Acid: A Population-Based Cohort Study |
title_full_unstemmed | Risk of Mortality among Patients with Gastrointestinal Bleeding with Early and Late Treatment with Tranexamic Acid: A Population-Based Cohort Study |
title_short | Risk of Mortality among Patients with Gastrointestinal Bleeding with Early and Late Treatment with Tranexamic Acid: A Population-Based Cohort Study |
title_sort | risk of mortality among patients with gastrointestinal bleeding with early and late treatment with tranexamic acid: a population-based cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951209/ https://www.ncbi.nlm.nih.gov/pubmed/35330064 http://dx.doi.org/10.3390/jcm11061741 |
work_keys_str_mv | AT tingkehsin riskofmortalityamongpatientswithgastrointestinalbleedingwithearlyandlatetreatmentwithtranexamicacidapopulationbasedcohortstudy AT shiubeihao riskofmortalityamongpatientswithgastrointestinalbleedingwithearlyandlatetreatmentwithtranexamicacidapopulationbasedcohortstudy AT yangshunfa riskofmortalityamongpatientswithgastrointestinalbleedingwithearlyandlatetreatmentwithtranexamicacidapopulationbasedcohortstudy AT liaopeilun riskofmortalityamongpatientswithgastrointestinalbleedingwithearlyandlatetreatmentwithtranexamicacidapopulationbasedcohortstudy AT huangjingyang riskofmortalityamongpatientswithgastrointestinalbleedingwithearlyandlatetreatmentwithtranexamicacidapopulationbasedcohortstudy AT chenyinyang riskofmortalityamongpatientswithgastrointestinalbleedingwithearlyandlatetreatmentwithtranexamicacidapopulationbasedcohortstudy AT yehchaobin riskofmortalityamongpatientswithgastrointestinalbleedingwithearlyandlatetreatmentwithtranexamicacidapopulationbasedcohortstudy |